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Linkage study of the low-density
lipoprotein-receptor gene and cholesterol levels
in an Afrikaner family
Quantitative genetics and identification of a minor founder effect
P. A. BRINK, L. T. BRINK, M. TORRINGTON, A. J. BESTER
Summary
Overlap of clinical and biochemical characteristics between
hypercholesterolaemia in members of the general population
and familial hypercholesterolaemic (FH) individuals may lead
to misdiagnosis. Quantitative analysis of family data may
circumvent this problem. A way of looking for an association
between plasma cholesterol levels and restriction fragment
length polymorphism markers (RFLP) on the low-density
lipoprotein (LDL) receptor gene by using reference choles-
terol distributions was explored. Linkage, with a logarithm of
the odds (LOO) score of 6,8 at (j 0, was detected between
cholesterol levels and the LDL receptor in an extended Afri-
kaner family. Two RFLP-haplotypes, one previously found in
a majority of Afrikaner FH homozygotes, and a second, Stu I
-, BstE 11 +, Pvu 11 +, Nco I +, were associated with high
cholesterol levels in this pedigree.
S Atr Med J 1990; 77: 292-296.
Familial hypercholesterolaemia (FH), an autosomal dominant
disease with a gene dosage effect, is characterised by raised
plasma cholesterol levels, tendon xanthomas, and an increased
risk of myocardial infarction at a young age. 1 Elevated choles-
terol levels are the result of an inability of abnormal low-
density lipoprotein (LDL) receptors to bind and internalise
LDL, a major cholesterol-carrying particle in the blood. l At a
prevalence of more than I: lOO among Afrikaners, FH is at
least 5 times more prevalent in this group than has been
described in other countries. 2 Evidence for founder effects
includes: (z) shared ancestors in the majority of FH subjects
(M. Torrington - unpublished data); (iz) a similar biochemical
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defect revealed in LDL-receptor studies on a host of FH
homozygotes;3 and (iiz) a single restriction fragment length
polymorphism (RFLP) haplotype present in a majority of FH
homozygotes:,5 In comparison, other haplotypes are known to
be present in FH patients from other groups of the South
African population (black, coloured and whites of non-Afri-
kaner origin (H. Henderson - personal communication).
The definitive diagnosis of heterozygous FH in individuals
can be difficult. A dividing point of a plasma cholesterol level
of 7 mmol/I between FH in the Afrikaner (as used by Seftel et
al. 6 ) and hypercholesterolaemia in members of the general
population will neither exclude nor diagnose gene carriers
every time. 7 For example, the population mean serum choles-
terol level for women aged between 55 years and 64 years is
17,6 mmol/J.7 Sex, age, population cholesterol background,
population frequency of FH and pedigree are important para-
meters to consider in the probability of an individual having
FH. Xanthomas, although virtually pathognomonic, are not
always present. FH homozygotes, however, seem to identify
themselves clearly, both at a clinical, plasma cholesterol and
studies at a cellular level.3
Instead of using absolute criteria for diagnosis, it is proposed
that quantitative diagnostic methods be explored. One way of
doing this is explored in this article, i.e. the identification of
linkage between an LDL receptor-associated RFLP haplotype
and cholesterol level. The probable haplotype origin could be
traced genealogically through 12 generations (see p. 289).8
Methods
General principles
A prior assumption of FH segregating in a pedigree is made
on the presence of early coronary heart disease, and/or xan-
thomas and a raised plasma cholesterol level in some indivi-
duals within the family. Cholesterol levels, adjusted to correct
for age and sex, are then tested for linkage to the LDL-
receptor locus using reference cholesterol phenotypic distribu-
tions for FH and for the general population.
Specific methods
The cholesterol levels of the individuals in this investigation
were adjusted to that of the age group 25 - 34 years using the
Population7
FH heterozygotes (N= 19)
FH homozygotes (N = 19)
formula, adapted from Goldstein er al.: 9 observed plasma
cholesterol level, minus mean level of plasma cholesterol in the
particular age and sex group to which the individual belongs,
plus the mean cholesterol level in the age group (25 - 34 years)
of the same sex.
The age group 25 - 34 years was selected as the standard to
adjust to since the reported difference between means and
standard deviations for male and female are least in this age
group when compared with other age groupS.7
For the FH phenorypic reference distributions a previously
well-characterised group of FH homozygotes and their obligate
heterozygotic parents were used. 3 Plasma cholesterol levels
were adjusted as described and the means and standard devia-
tions are shown in Table 1. For the general population pub-
lished phenotype plasma cholesterol values for the age group
25 - 34 years were used.7Normal distributions of the adjusted
plasma cholesterol values were assumed and standard devia-
tions calculated. The age group < IS years was treated as if
belonging to the group IS - 19 years; those> 64 years as 64
years.
TABLE I. REFERENCE DISTRIBUTIONS: MEANS AND
STANDARDS (mmol/l CHOLESTEROL)
Mean Standard
5,72 1,31
8,62 1,23
21,49 3,91
No transformation was done on triglycerides, since this was
not used for analysis.
Genotype likelihoods for given phenotypes, and from the
likelihoods of logarithm of the odds (LOD) scores,IO were
calculated to determine the most probable recombination frac-
tion between the trait and the marker locus. This calculation
was done on a personal computer with the LIPED genetic
linkage program developed by On, II using RFLP and trans-
formed cholesterol data from individuals, population
RFLP frequencies and the parameters of the reference choles-
terol distributions. A LOD score of more than 3 for a recombi-
nation fraction e less than 0,5 was accepted as evidence of
linkage. IQ Closeness of linkage depended on where the LOD
score peaked between eo and 0,5.
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RFLPs at the LDL receptor locus were detected using
methods previously described by our group.4. The two alleles
for each DNA restriction enzyme used were called '-' or '+',
where '-' and '+' denotes the absence or presence of a
restriction site. Subjects were a ked to fast for 12 hours before
blood was drawn. Lipograms were performed by the Tygerberg
Hospital chemical pathology laboratory.
Results
Relevant pedigree, clinical, biochemical and genetic data are
shown in Fig. 1 and Table 11.
Four RFLPs were identified by DNA restriction enzymes,
namely Pvu 11,12 Sw 1,13 BsrE 11 14 and Nco 1. 15 The highest
LOD score for a single enzyme was 3,5 at e°for Sw 1.
On examining the pedigree it was clear that only certain
individuals were informative for Sw 1. None of the 4 enzymes
used in isolation were informative in all pedigree members.
Therefore, assuming no recombination at an intragenic level,
the haplotypes formed by the 4 RFLPs were used to recalculate
the LOD score. Out of 16 possible combinations of the 4
RFLPs, 6 haplotypes have been identified in the general
population (Fig. 2). Most pedigree members were informative
for this allele system of 6 haplotypes. By using these haplotypes
as markers the LOD score was recalculated and a score of 6,8
at e°was obtained.
By inspection it was clear that in this pedigree two haplo-
types, a common one previously shown to be present in a
majority of Afrikaner FH homozygotes (since extended to 4
RFLPs, haplotype No. I, Fig. 24) and a second haplotype
(haplotype TO. 2, Fig. 2) are segregating. Individuals 4.9, 4.11
and some of their affected sibs (Fig. I) carry the laner
haplotype. This second haplotype has also been identified in a
single family in the previously described host of homozygotes
(kindred 2)4 and in another Cape family. A common ancestral
link between individuals 4.9 and 4.11 in the pedigree (Fig. I),
kindred 24 and the other Cape family could be traced to an
immigrant(s) who came to the Cape 12 generations ago in 1692
(see Torrington and BrinkS).
Discussion
In this study a quantitative way of testing linkage was explored,
and close linkage was detected between the LDL-receptor
locus and cholesterol levels in an extended pedigree in which
KEY
o MALE
o FEMALE!i DEAD
HAPLOTYPE 1
~ 0 HAPLOTYPE 2
•• HAPLDTYPES 1 AND 2
nt NOT TESTED
... PROBAND
Fig. 1. The segregation of haplotypes 1 and 2 is ~ho~~. It.g.enerally coincides .with high (> 7 mmolll) ~djusted plasma cholesterol
levels as can be verified from Table 11. An exception IS mdlvldual 6.1 whose adjusted cholesterol level IS 6,98 mmol/l. However the
latter person inherited haplotype 2 and therefore FH. Note that unrelated in.divid.uals 4.9 and 4.11 share the same RFLP haplotype.
The latter's haplotype could be deduced from the known haplotypes of hiS. children and spouse. ~f interest are individuals 5.10
and 5.25 who inherited both haplotypes 1 and 2. They also have both the highest absolute and adjusted cholesterol levels in the
pedigree. This agrees with the inheritance of two genes (a double dose) at the same locus causing hypercholesterolaemia.
TABLE 11. SUMMARY OF CHOLESTEROL, CLINICAL AND HAPLOTYPE DATA OF PEDIGREE
Cholesterol
I N10Adjusted Haplotype ,.
Pedigree Age Triglyceride Total cholesterol HDL total Tendon Myocardial SBPNposition* (yrs) Sex (mmol/l) (mmol/l) levels (mmol/l) cholesterol xanthoma infarction S B P Nl Comment (J)M }>2.2
- - - -
- - -
- d, 35, heart disease s:
c..2.7
-
F
- -
- - - -
- d, 80, heart disease3.1 M d, 50, heart disease <- - - - - - - - 03.4 F d, 53, heart disease r- - - - - - - -
'"3.5 M d, 56, heart disease '"- - - - - - - (+----)3.10 85 F 1,55 6,55 5,11 0,24
- - -
::::;(+ - - +) s:(+_:.... -) }>3.11
- - - - Deduced haplotype, :Xl(++++) d, 81, heart disease iD+--+ <D4.3 63 F 2,18 6,03 5,52 0,20 0
- -
-+--+
4.4 65 M 0,91 8,79 8,17 0,16 + -+++ 58, MI- +-++
4.5
- F
4.6
-
M
- - - - - -
'+ --=t- + d, 61, heart disease4.7 71 F 1,35 7,51 5,87 0,19
- -
-
4.8
-
M
- - - -
(±+++)
Deduced haplotype,( ? ) d, 50, heart disease
-+++4.9 69 M 0,79 10,37 9,75 0,08 +
- ....
4.10 57 F 0,58 8,89 7,25 0,11 +---
- -
+--+
4.11
- M - - - - - (++-+) Deduced haplotype(-+++)
d, 46, heart disease+---4.12 56 F 1,79 15,42 13,78 0,09
- -
+--+
4.14 64 F 2,22 9,56 7,92 0,14 +---
- -
++++
4.15 53 F 2,65 8,09 6,98 0,12 +--+
-
- ++++
4.16 51 F 3,71 8,58
- 0,09
4.17
-
M
-
- - - -
- - d, 40, heart disease
4.18
-
M
- -
- - - - +---- d, 35, heart disease4.20 44 F 0,93 10,76 10,40 0,12
- - +---M -4.21 42 4,08 12,95 12,51 0,07
-
- +---
5.1 22 F 0,67 4,42 4,83 0,25 ++++
- -
++++
5.2 38 M 1,46 7,75 7,31 0,14 -+++
- -
.±++"t5.3 32 F 0,75 7,62 7,62 0,16
- -
+==+5.5 39 F 0,68 6,91 6,55 0,20
- - ±+++5.6 48 M 0,82 8,99 8,32 0,10 +
- +-++
5.7
- M - - - -
- - + +-=t- + d, 19, SO5.8 30 M 1,22 11,99 11,99 0,09
- -
+---
5.9 39 M 0,89 4,63 4,19 0,22 - - +----5.10 32 F 0,54 17,58 17,58 0,05 + - Clinical homozygote
5.11 40 F 0,44 4,73 4,37 0,28
5.12 41 M 1,24 6,29
- 0,14
-+++
5.14 39 F 0,31 4,99 4,63 0,27 ++++
- -
5.16 37 M 0,74 4,97 0,23 ~~:;:::;::+- - - +--+
5.17
- M - - - - - - - d, 14, heart disease
5.18 - M - - - - - - d, 14, heart disease
5.19 27 M 0,99 7,20 7,20 0,10 +---
- -
5.21 34 M 1,46 5,10 5,10 0,15 +±:;::+- - +---
5.22 30 F 0,60 7,89 7,89 0,15 -+++
- -
5.23 22 F 2,66 9,60 10,01 0,13 +:;::=+
- - +---
5.24 25 F 0,70 5,38 5,79 0,28 +--+- -
5.25 17 M 0,25 17,08 19,39 0,03 + t±=± Clinical homozygote-
-+++
5.26 20 F 0,45 10,09 11,03 0,11 -+++
- - +--+
6.1 6 M 0,36 5,69 6,98 0,20 +-++- -
-+++
6.2 8 M 0,56 7,34 8,63 0,15 +-++- -
-+++
6.3 11 M 0,7. 8,39 9,68 0,12 +-++
- -
-+++
6.4 8 F 0,46 4,76 5,40 0,29 +-++- - +-++
6.5 13 F 0,61 4,58 5,22 0,25 +-++- - +-++
6.6 16 F +-++- - - - - - ++-+
6.7 8 F 0,55 6,92 - 0,24 - - - - (J)
6.8 6 F 0,55 7,25 0,24 »- - - - - ;::
6.9 8 M 0,38 4,06 - 0,23 - - - - -l
6.11 7 F 0,69 4,29
-
0,19 - - - - <0
6.12 14 F 0,60 4,94 - 0,26 - -
-+-++ -
!
6.14 14 F 0,44 4,50 0,31 ....- - - -
"++++
F -+++
::::,
6.15 16 0,59 5,02 - 0,24 - - - ;::+--+ »
:D
6.16 11 F 0,74 5,43 - 0,23 - - ~- - <D
F 3,07 <D6.17 8 0,81 - 0,24 - - +---+ - 0
6.18 8 M 0,57 3,51 4,80 0,33 + - +-++
I I\)ID*Refers to tndlvlduals as they appear In pedIgree In Fig. 1. UI
tS 8 P N denotes haplotypes Of variable restriction sItes Identified by the enzymes Slu l. BstE n, Pvu 11, Nco I in the order that they appear on the LDL-receptor gene. (- = absence; + = presence of a restriction site),
HOL =high-density lipoprolein; d =died; numeral = age (yrs); MI =myocardial Infarction; SO =sudden dealh.
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exon no. 5 6 7 8 910 11 12 13 14 15 16 17 18gene
---9 1 I 1I !I 1 11___- I - --
Stu 85 tE 11 Pvu 11 I co
Fig. 2. Position of, and haplotypes formed by, variable restriction
sites for enzymes used. Shown horizontally is a linear diagram of
the 3' end of the LDL receptor gene. Dark areas with numerals
5 - 18 at the top indicate exonsY Shown below the restriction map
are haplotypes 1 - 6 detected in the general population. Haplo-
types 1 and 2 segregate with FH in this study.
some members have typical FH. The identification of a linked
RFLP haplotype allows founder members to be identified.8
Instead of making the diagnosis of FH in specific individuals,
a previous assumption of FH segregating in the pedigree was
made. A bi- or tri-modal distribution of cholesterol level was
to be expected if this assumption was true. However, the effect
of a defective LDL receptor can be masked by factors such as
sex, age, population lipid profile and other unknown elements.
An adjustment to a uniform age and sex was therefore neces-
sary. In a small data set it can be difficult to differentiate
between a skewed distribution and a bi- or tri-modal distri-
bution. For this reason, a reference distribution was created.
In the presence of strong evidence of close linkage (an LOD
score of 6,8 at 6 0), it can be accepted that the assumption of a
tri-modal distribution is correct and that the LDL receptor
locus plays a causal role. 10 This does not exclude the possibility
that a gene closely linked to the LDL receptor may be causing
the raised cholesterol levels. The larrer possibility is, however,
unlikely. No gene associated with cholesterol metabolism that
is close to the LDL receptor gene has been described. The
previous probability of finding another cholesterol-associated
gene in this way has been calculated l6 as 0,005.
A criticism that may be levelled is that the reference data
are not ideal. For example, published South African population
lipid data do not include figures for people aged 2 - IS years
and over 65 years. Another possible criticism is that the 14
families, members of which were used to create the FH
reference groups, were not closely related but taking data from
all 19 available homozygotes from these 14 families means that
5 sibling pairs were used. However, FH homozygotes are rare
in the population and this is the only host of Afrikaner
homozygotes and their parents that is well defined.3 The data
are probably valid only for this population group at present.
Changes in lifestyle and diet may change the assumptions
about the reference distributions in the future.
Risk associated with FH may have been different in the
past. It should be noted that members of generations 2 and 3
in respect of haplotype I arrained ages well above those
generally observed in this form of FH. Factors other than
defects at the LDL receptor-gene locus may have contributed
to this. Quite a few early deaths were, however, recorded in
previous generations for the line of descent of haplotype No.
2, so there may perhaps be a difference in severity between the
two genotypes.
It is felt that the method advocated in this article could be
useful in establishing the presence of PH - by FH a LDL
receptor defect is assumed - in families. It should be espe-
cially useful in families in which a suspicion of the presence of
1)
2)
3)
~)
6) +
+
+
+
FH exists but pathognomonic signs, such as xanthomas or a
FH homozygote (most families), are not present.
Another way of addressing the problem of diagnosing FH is
using a semi-quantitative approach with percentiles. However,
the 90th percentile for plasma cholesterol levels is not effective
enough. 7 If FH does occur at 1:100 in the Afrikaner group and
if plasma cholesterol levels are mostly above the 90th percentile
it still means that only I: 10 above this percentile will have FH.
It should be possible - using a Bayesian approach that takes
into account percentiles, population frequency of polymor-
phisms, FH frequency and pedigree structures - to develop
effective diagnostic formulas for the Afrikaner group or other
genetically defined groups.
Since FH among Afrikaners - as a result of the hypo-
thesised founder effects - is expected to be the result of a
small number of mutations, it is expected that routine tests
that detect the exact mutations in this group will become
available and that the use of linked markers will not then be
necessary. However, FH as a result of other mutations also
exists in other population groups in this country and presents
a challenge in diagnosis. Some Afrikaner FH families do not
belong to the founder groups. In addition, other factors that
play a role in lipid metabolism have to be elucidated. For
example, as is being done elsewhere,17 the role that different
apolipoproteins play in South African populations can be
examined at a genetic level. The techniques of genetic epi-
demiology and molecular genetics should prove invaluable in
addressing the problem of heart disease in the family context.
The laboratory of the Department of Chemical Pathology at
Tygerberg Hospital is thanked for doing the lipid analyses.
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